CURRICULUM VITAE
FOR
CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE

AUGUST 14, 2025

PERSONAL INFORMATION
Name; last, first middle Mustafa Ali, Moaath K.
Credentials; MD, PhD, etc. MD, MPH

Institution / Institute Cleveland Clinic, Taussig Cancer Center
Department Hematology and Medical Oncology, Leukemia Division
Office Address & Mail Code 10201 Carnegie Ave, Cleveland, OH 44106
Office Phone 216-442-5557
Office Email [email protected]

Home Address (Optional) 33436 Santa Marie CT, Avon, OH 44011

EDUCATION & TRAINING
Education
School & City, State / Country University of Jordan School of Medicine, Amman, Jordan
Degree Medical Doctor
Start-End Dates 9/2006-6/2012

School & City, State / Country Johns Hopkins School of Public Health, Baltimore, MD
Degree Master of Public Health
Start-End Dates 12/2018-12/2020

School & City, State / Country Johns Hopkins School of Public Health, Baltimore, MD
Degree Clinical Trial Design Certification
Start-End Dates 12/2018-12/2020

School & City, State / Country Johns Hopkins Krieger School of Arts and Sciences, Washington, DC
Degree Master's Degree in Biotechnology
Start-End Dates 9/2023-Current

Post-Graduate Training
Institution & City, State / Country Al-Issra Hospital, Amman, Jordan
Position Internship
Start-End Dates 7/2012-6/2013

Institution & City, State / Country King Hussein Cancer Center, Amman, Jordan
Position Resident, Internal Medicine
Start-End Dates 7/2013-6/2014

Institution & City, State / Country Cleveland Clinic Foundation, Cleveland, Ohio
Position Resident, Internal Medicine-Clinical Scholar Track
Start-End Dates 7/2014-6/2017

Institution & City, State / Country University of Maryland School of Medicine
Position Fellow, Hematology and Medical Oncology
Start-End Dates 7/2019-6/2022

PROFESSIONAL APPOINTMENTS
Position Assistant Professor of Medicine
Institution / Institute Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.
Department Hematology and Medical Oncology
Start-End Dates 4/2023-present

Position Associate Staff
Institution & Institute Cleveland Clinic, Taussig Cancer Institute, Hematology and Medical Oncology
Department Hematology and Medical Oncology
City, State / Country Cleveland, Ohio.
Start-End Dates 7/2022-present

Position Clinical Assistant Professor/ Academic Hospitalist
Institution / Institute University of Toledo School of Medicine/ ProMedica Toledo Hospital, Toledo, Ohio.
Department Internal Medicine
Start-End Dates 7/2017-6/2019

ADDITIONAL CAREER DEVELOPMENT
Leadership Development
School / Institution Family International Community Services
Title /Certificate Motivational Volunteer Empowerment Program (MOVE-2009)
Start-End Dates 7/2009-10/2009

School / Institution Cleveland Clinic Foundation
Title / Certificate Clinical Scholar Program (ClinSchoP)
Start-End Dates 7/2015-12/2015

Educator Development
School / Institution University of Jordan
Title / Certificate How to become an effective educator?
Start-End Dates 2/2011-4/2011

School / Institution Cleveland Clinic Foundation
Title / Certificate Clinical Scholar Program (ClinSchoP)
Start-End Dates 7/2015-12/2015

School / Institution Cleveland Clinic Foundation
Title / Certificate Internal medicine Boot Camp for Senior Residents
Start-End Dates 7/2015-/2015

Clinical Development
School / Institution Cleveland Clinic Foundation
Title / Certificate Internal Medicine Boot Camp
Start-End Dates 7/2014-8/2014

School / Institution University of Maryland School of Medicine
Title / Certificate Hematology and Medical Oncology fellowship Boot camp
Start-End Dates 7/2019-8/2019

CERTIFICATION & LICENSURE
Certification
Name of Board American Board of Internal Medicine- Internal Medicine
Certificate Number (if applicable) 376485
Date Issued & Expires 2017-2027

Name of Board American Board of Internal Medicine- Medical Oncology
Certificate Number (if applicable) 376485
Date Issued & Expires 2022-2032

Name of Board American Board of Internal Medicine- Hematology
Certificate Number (if applicable) 376485
Date Issued & Expires 2022-2032

Licensure
Name of State Medical Board Ohio Medical Board
License Number 35.129504
Date Issued & Expires 2016-2026

Name of State Medical Board Pennsylvania State Board of Medicine
License Number MD470751
Date Issued & Expires 2020-2022

MEMBERSHIP IN PROFESSIONAL SOCIETIES
Name of Society International Federation of Medical Students' Associations
Role / Title Member
Start-End Dates 2007-2012

Name of Society Operation Smile
Role / Title Member
Start-End Dates 2010-2013

Name of Society American Society of Hematology
Role / Title Member
Start-End Dates 2015-present

Name of Society American Society of Clinical Oncology
Role / Title Member
Start-End Dates 2015-2022

Name of Society Jordan American Physician Association
Role / Title Medical Research Committee Member
Start-End Dates 2021-present

Name of Society National Comprehensive Cancer Network
Role / Title Acute Myeloid Leukemia Panel Member
Start-End Dates 2022-present

PROFESSIONAL SERVICES
Manuscript Reviewer
Frontiers in Oncology
2022-present

Signal Transduction and Targeted Therapy
2024-present

Abstract Reviewer
ASH Abstracts Reviews: 2023 National Meeting 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Therapies for ALL

ASH Abstracts Reviews: 2024 National Meeting 637--Myelodysplastic Syndromes: Clinical and Epidemiological

ASH Abstracts Reviews: 2025 National Meeting To be declared post-meeting

Oral Abstract Session Moderator

ASH Abstracts Moderator: 2023 National Meeting 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Therapies for ALL

ASH Abstracts Moderator: 2024 National Meeting 637--Myelodysplastic Syndromes: Clinical and Epidemiological

Editorial Role
Associate Editor, JAPA Academy Medical Journal (2025)

Columnist
Blood Cancer Today – Columnist for Malignant Hematologic Neoplasms (2025)

COMMITTEE SERVICE
Hospital Affiliate
Organization Cleveland Clinic Taussig Cancer Center
Committee Name / Role Taussig Innovations Council/ Member
Start-End Dates 7/2022-Current

Organization University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center
Committee Name / Role Clinical Research Committee/ Reviewer
Start-End Dates 12/2020-6/2022

Organization University of Maryland Medical Center
Committee Name / Role Transfusion Committee/ Member
Start-End Dates 7/2020-6/2021

Organization ProMedica Toledo Hospital
Committee Name / Role Cardiac Resuscitation Committee/ Member
Start-End Dates 10/2017-6/2019

Educational Committees
Organization University of Toledo
Committee Name / Role Internal Medicine Residency Candidate Committee/ Member
Start-End Dates 10/2017-6/2019

HONORS & AWARDS

1. Doctor Waleed Al-Maani's Award for Scientific Excellence, University of Jordan School of Medicine
Awarded for distinguished performance in medicine. (2012)
2. Valedictorian, University of Jordan School of Medicine
Awarded for ranking first in the graduating class. (2012)
3. Annual Meeting Merit Award, American Society of Clinical Oncology / Conquer Cancer Foundation
“Prevalence, risk factors and attenuators of patient-reported concerns among breast cancer survivors.” (2016)
4. Annual Meeting Merit Award, American Society of Clinical Oncology / Conquer Cancer Foundation
“Autologous stem cell transplantation (ASCT) versus whole brain radiation (WBRT) as a consolidation therapy in primary CNS lymphoma (PCNSL): A nationwide analysis.” (2021)
5. Fellow Pilot Project Research Grant Award, University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center (2021)
6. Best ASH In-Service Score, University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center (2022)
7. Best ASCO In-Service Score, University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center (2022)
8. Appreciation Award – Empathy, Cleveland Clinic Foundation
Awarded for being the top performer for HCAHPS Doctor Communication (12 months ending 03/31/2023). (2023)
9. Appreciation Award – Patient Care, Cleveland Clinic Foundation
Awarded for performing at or above the 90th percentile in HCAHPS Doctor Communication (12 months ending 12/31/2024). (2024)
10. Research Mentor of the Year, Cleveland Clinic Foundation, Internal Medicine Residency
Awarded for exceptional guidance and support in resident research, fostering academic curiosity and success. (2025)

TEACHING ACTIVITIES
Grand Rounds
Local
1. “A Phase I Trial of Calaspargase Pegol-mknl in Combination with High Dose Cytarabine and Idarubicin in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia”. University of Maryland Medical Center, Hematology and Medical Oncology Department: staff and trainees, 12/2021
2. “Combining PP2A Activators With FLT3 Inhibitors To Overcome FLT3 Inhibitor Resistance In AML”. University of Maryland Medical Center, Hematology and Medical Oncology Department, 6/2022

Other Presentations
Local
1. “Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia”, Hematology/Oncology Journal Club, Hematology and Medical Oncology Department: staff and trainees, 8/2020.
2. “Protein Phosphatase 2A and Oncologic Implications”, Hematology/Oncology Contemporary Topics Conference, Hematology and Medical Oncology Department: staff and trainees, 4/2021.
3. “The effect of FLT3 inhibitor combination with PP2A-activating drug on Mcl-1 expression and turnover in acute myeloid leukemia with FLT3-ITD”, Joint Lab Meeting, Hematology and Medical Oncology Department: staff and trainees, 5/2021.
4. “Anti-factor XI for postoperative thromboembolism prophylaxis”, Hematology/Oncology Didactics, Hematology and Medical Oncology Department: staff and trainees, 8/2021.
5. “ASCO Plenary Recap: A Sample from the Sea”, Hematology/Oncology Didactics, Hematology and Medical Oncology Department: staff and trainee, 9/2021.
6. “Acute Leukemia: What Does the Internist Need to Know”, Internal Medicine Residency Didactics, Internal Medicine Department: staff and trainee, 12/2021.
7. “Melanoma made ridiculously simple”, Hematology/Oncology Didactics, Hematology and Medical Oncology Department: staff and trainee, 2/2022.
8. “Basics of Medical Research 1: Definition, Data Types and How to Compare Data”, Cleveland Clinic Internal Medicine Residency Lecture series: staff and trainees, 2/2023
9. “Basics of Medical Research 2: Sampling errors, Confidence Intervals and Hypothesis Testing”, Cleveland Clinic Internal Medicine Residency Lecture series: staff and trainees, 4/2023
10. “Basics of Medical Research 3: Confounding, Interaction, Regression”, Cleveland Clinic Internal Medicine Residency Lecture series: staff and trainees, 5/2023
National
1. “Highlights of ASH 2023: Acute Myeloid Leukemia”, Sixth Annual Review of Hematology and Immunotherapy, University of Kentucky. University of Kentucky medical staff, including hematologists/ oncologists, pharmacists, nurses, and other ancillary staff, 02/2024.

Trainees / Mentees
1. Marwa M. Sabha, Sarah K. Mustafa, Momen Banifadel, Sami Ghazaleh, Kanana M Aburayyan, Marcel T. Ghanim, Mohammed T. Awad, Damynus N. Gekonde, Amala R. Ambati, Ahmad Ramahi, Ahmed M. Elzanaty, Zeid Nesheiwat, Pinang M Shastri, Mohammad Al-Sarie, , University of Toledo. Medical Research (supervised internal medicine residents in conducting a prospective cohort study, that is published), 2017-2019.
2. Elizabeth Corely, MD; candidate, University of Maryland. Medical Research (supervised her in building AML database at University of Maryland and writing two published original articles), 2019-2022. Currently internal medicine resident at Cornell, NY.
3. Fahad Alkaaba, MD; internal medicine resident, University of Maryland. Medical Research (supervised him in writing two original articles), 2020-2022. Currently internal medicine resident at University of Maryland.
4. Matthew Williams, MD; internal medicine resident, University of Maryland. Medical Research (supervised him in writing one original articles), 2020-2022. Internal medicine resident at University of Maryland.
5. Hadil Zureigat, MD; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised her in developing three clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
6. Bridget Adcock, MD; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised her in developing two clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
7. Asad Rauf, MD; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised him in developing two clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
8. Paul Nurse, DO; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised him in developing two clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
9. Heya Batah, MD; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised her in developing one clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
10. Naveen Rehman, MD; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised her in developing one clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
11. Aastha Dhakal, MD; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised her in developing one clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
12. Muaz Alsabbagh Alchirazi, MD; post-doc fellow, Cleveland Clinic Foundation. Medical Research (supervised him in developing several clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
13. Ahmed Nabil Mohamed Hassan, MBBCh; post-doc fellow, Cleveland Clinic Foundation. Medical Research (supervised him in developing several clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
14. Moath Albliwi, MD; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised him in developing several clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
15. John Hanna, MD; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised him in developing several clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
16. Ali Mushtaq, MD; internal medicine resident, Cleveland Clinic Foundation. Medical Research (supervised him in developing several clinical studies), 2022-present. Internal medicine resident at Cleveland Clinic Foundation
17. Ameed Bawwab, MD; hospitalist, Cleveland Clinic Foundation. Medical Research (supervised him in developing several clinical studies), 2022-present. Hospitalist at Cleveland Clinic Foundation
18. Hasan Abuamsha, MD; hospitalist, Cleveland Clinic Foundation. Medical Research (supervised him in developing several clinical studies), 2022-present. Hospitalist at Cleveland Clinic Foundation
19. Yomna Abu-Farsakh, MD; Primary Care Physician, Assistant Professor of Internal Medicine, Northeast Ohio Medical University. Medical Research (supervised her in developing several clinical studies), 2022-present. Primary Care Physician, Aultman Hospital
20. Jessica El-Asmar, MD; hematology and medical oncology fellow, Cleveland Clinic Foundation. Medical Research (supervised her in developing several clinical studies), 2022-present. Hematology and medical oncology fellow at Cleveland Clinic Foundation

Teaching Administration
1. Attending Physician, inpatient teaching service, Promedica Toledo Hospital, 1 resident, 3 interns, medical students, 12 hours/day, 4 months/year. 2017-2019
2. Attending Physician, inpatient and outpatient services, Cleveland Clinic Taussig Cancer Center, 1-3 medical students +/- internal medicine resident +/- hematology and oncology fellow, 30 hours/week, 11 months/ year, 2022-current

Teaching Activities
1. Lecturer: Journal club, Case Presentation, Conference, Cleveland Cinic, 15 contact hours/ year, staff and medical trainees, 2014-2017
2. Lecturer: Journal club, Case Presentation, Conference, Promedica Toledo Hospital, 15 contact hours/ year, staff and medical trainees, 2017-2019
3. Lecturer: Journal club, Case Presentation, Conference, Promedica Toledo Hospital, 15 contact hours/ year, staff and medical trainees, 2019-2022

RESEARCH / GRANT SUPPORT
Grant Supported
Sponsor Agency and ID # University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center
Title “PP2A-activating drugs to overcome FLT3 inhibitor resistance in acute myeloid leukemia with FLT3-ITD”
Description / Information Annual award to one of the fellows in the hematology and medical oncology fellowship for be best research project
Your Role Co-PI
Percent Effort 100%
Percent Salary Support 0%
Total Direct Costs Awarded $5000
Start-End Dates 7/2021-6/2022

BIBLIOGRAPHY
Peer Reviewed Articles (*Co-first author)
1. Zayed AA, Mustafa Ali MK, Al-Ani MA, Momani MS, Yousef AM. The prevalence of isolated growth hormone deficiency among children of short stature in Jordan and its relationship with consanguinity. Clin Endocrinol (Oxf). 2014 Dec;81(6):876-82. doi: 10.1111/cen.12510. Epub 2014 Jul 7. PubMed PMID: 25041402.
2. Mustafa Ali MK, Sabha MM, Al-Rabi KH. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment. Platelets. 2015;26(5):491-4. doi: 10.3109/09537104.2014.935316. Epub 2014 Jul 15. PubMed PMID: 25025538.
3. Abdullah SY, Mustafa Ali MK, Sabha MM. Type-B lactic acidosis associated with progressive multiple myeloma. Saudi Med J. 2015 Feb;36(2):239-42. doi: 10.15537/smj.2015.2.10205. PubMed PMID: 25719593; PubMed Central PMCID: PMC4375706.
4. Zayed AA, Mustafa Ali MK, Jaber OI, Suleiman MJ, Ashhab AA, Al Shweiat WM, Momani MS, Shomaf M, AbuRuz SM. Is Hashimoto's thyroiditis a risk factor for medullary thyroid carcinoma? Our experience and a literature review. Endocrine. 2015 Mar;48(2):629-36. doi: 10.1007/s12020-014-0363-2. Epub 2014 Jul 24. Review. PubMed PMID: 25056007.
5. Mustafa Ali M, Ruano Mendez AL, Carraway HE. Hemophagocytic Lymphohistiocytosis in a Patient With Hodgkin lymphoma and Concurrent EBV, CMV, and Candida Infections. J Investig Med High Impact Case Rep. 2017 Jan-Mar;5(1):2324709616684514. doi: 10.1177/2324709616684514. eCollection 2017 Jan-Mar. PubMed PMID: 28210636; PubMed Central PMCID: PMC5298562.
6. Mustafa Ali M, Abounader DM, Rybicki LA, Yurch MA, Starn J, Ferraro C, Winslow V, Hamilton BK, Gerds AT, Liu H, Dean R, Hill BT, Pohlman B, Andresen S, Hanna R, Kalaycio M, Bolwell BJ, Majhail NS, Sobecks RM. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2017 May;23(5):776-781. doi: 10.1016/j.bbmt.2017.01.077. Epub 2017 Jan 17. PubMed PMID: 28108271.
7. Mustafa Ali M, Moeller M, Rybicki L, Moore HCF. Long-term peripheral neuropathy symptoms in breast cancer survivors. Breast Cancer Res Treat. 2017 Nov;166(2):519-526. doi: 10.1007/s10549-017-4437-8. Epub 2017 Aug 8. PubMed PMID: 28791499.
8. Mustafa Ali M, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT, Jagadeesh D, Pohlman B, Hsi ED, Smith MR. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):797-803. doi: 10.1016/j.clml.2017.07.002. Epub 2017 Jul 13. PubMed PMID: 28789937.
9. Mustafa Ali M, Moeller M, Rybicki L, Moore HCF. Prevalence and correlates of patient-reported symptoms and comorbidities in breast cancer survivors at a tertiary center. J Cancer Surviv. 2017 Dec;11(6):743-750. doi: 10.1007/s11764-017-0612-5. Epub 2017 Mar 10. PubMed PMID: 28283875.
10. Mustafa Ali M, Corrigan DM, Rybicki LA, Yurch MA, Cherni K, Liu H, Dean R, Hamilton B, Pohlman B, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS, Sobecks R. Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma. Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):253-256. doi: 10.1016/j.hemonc.2018.03.006. Epub 2018 Apr 24. PubMed PMID: 29705567.
11. Lutfi F, Holtzman N, Siglin J, Bukhari A, Mustafa Ali M, Kim D, Sanchez-Petitto G, Gottlieb D, Ruehle K, Hutnick E, Gahres N, Hankey K, Lee S, Kocoglu M, Yared J, Hardy N, Rapoport A, Dahiya S. Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma. Br J Haematol. 2021 Jan;192(1):212-216. doi: 10.1111/bjh.17121. Epub 2020 Nov 10. PubMed PMID: 33169845.
12. Mustafa Ali MK, Sabha MM, Mustafa SK, Banifadel M, Ghazaleh S, Aburayyan KM, Ghanim MT, Awad MT, Gekonde DN, Ambati AR, Ramahi A, Elzanaty AM, Nesheiwat Z, Shastri PM, Al-Sarie M, McGready J. Hospitalization and Post-hospitalization Outcomes Among Teaching Internal Medicine, Employed Hospitalist, and Locum Tenens Hospitalist Services in a Tertiary Center: a Prospective Cohort Study. J Gen Intern Med. 2021 Jan 25;. doi: 10.1007/s11606-020-06578-4. [Epub ahead of print] PubMed PMID: 33495887; PubMed Central PMCID: PMC7832420.
13. Kashanian SM, Li AY, Mustafa Ali M, Sutherland ME, Duong VH, Hambley BC, Zacholski K, El Chaer F, Holtzman NG, Imran M, Patzke CL, Cornu J, Duffy A, Dezern AE, Gojo I, Norsworthy KJ, Levis MJ, Smith BD, Baer MR, Ghiaur G, Emadi A. Increased body mass index is a risk factor for acute promyelocytic leukemia. EJHaem. 2021 Feb;2(1):33-39. doi: 10.1002/jha2.163. Epub 2021 Jan 6. PubMed PMID: 33693438; PubMed Central PMCID: PMC7943182.
14. Hemmo S, Naser A, Alwafi H, Mansour M, Alanazi A, Jalal Z, Alsairafi Z, Paudyal V, Alomari E, Al-Momani H,, Salawati E, Samannodi M, Dairi M, Al Bawab A, Mustafa Ali M, Alkharabsheh S. Hospital Admissions Due to Ischemic Heart Diseases and Prescriptions of Cardiovascular Diseases Medications in England and Wales in the Past Two Decades. Int. J. Environ. Res. Public Health. 2021, 18(13), 7041; https://doi.org/10.3390/ijerph18137041
15. Scarpa M, Kapoor S, Tvedte E, Doshi K, Zou Y, Singh P, Lee J, Chatterjee A, Mustafa Ali M, Bromley R, Hotopp J, Rassool F, Baer M (2021) Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. Oncotarget. 2021 Aug 31;12(18):1763-1779. doi: 10.18632/oncotarget.28042.
16. Naser AY, Mansour MM, Alanazi AFR, Sabha O, Alwafi H, Jalal Z, Paudyal V, Dairi MS, Salawati EM, Alqahtan JS, Alaamri S, Mustafa Ali MK. Hospital admission trends due to respiratory diseases in England and Wales between 1999 and 2019: an ecologic study. BMC Pulm Med. 2021 Nov 8;21(1):356. doi: 10.1186/s12890-021-01736-8. PMID: 34749696; PMCID: PMC8573565.
17. Lutfi F, Holtzman NG, Kansagra AJ, Mustafa Ali M, Bukhari A, Yan J, Samanta S, Gottlieb D, Kim DW, Matsumoto LR, Gahres N, Ruehle K, Lee ST, Law JY, Kocoglu MH, Atanackovic D, Yared JA, Hardy NM, Molitoris J, Mohindra P, Rapoport AP, Dahiya S. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma. Br J Haematol. 2021 Nov;195(3):405-412. doi: 10.1111/bjh.17738. Epub 2021 Sep 9. PMID: 34500492.
18. Kim D, Bukhari A, Lutfi F, Zaffaroni F, Merechi F, Mustafa Ali M, Gottlieb D, Lee S, Kocoglu M, Hardy N, Yared J, Rapoport A, Dahiya S, Law J. Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Leuk Lymphoma. 2022 Jan 19;1-9. doi: 10.1080/10428194.2021.2024817.
19. Corley EM, Mustafa Ali MK, Alharthy H, Kline KAF, Sewell D, Law JY, Lee ST, Niyongere S, Duong VH, Baer MR, Emadi A. Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study. Front Oncol. 2022 Mar 18;12:804961. doi: 10.3389/fonc.2022.804961. PMID: 35372066; PMCID: PMC8972959.
20. Mustafa Ali MK, Corley EM, Alharthy H, Kline KAF, Law JY, Lee ST, Niyongere S, Duong VH, Emadi A, Baer MR. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study. Front Oncol. 2022 Mar 31;12:858202. doi: 10.3389/fonc.2022.858202. PMID: 35433414; PMCID: PMC9008336.\
21. Samhouri Y*, Mustafa Ali M*, Jayakrishnan T, Bakalov V, Fazal S, Kahn C, Wegner RE, Lee ST, Lister J. Survival Outcomes of Chemotherapy, Radiation and Combined Modality in Elderly Patients with Primary CNS Lymphoma; a 12-year Population-Based Analysis Using Propensity Score. Anticancer Res. 2022 Apr;42(4):1867-1877. doi: 10.21873/anticanres.15663.
22. Samhouri Y, Mustafa Ali MK*, Law J, Khan C, Wegner R, Lee ST, Lister J. Consolidative Autologous Stem Cell Transplantation Versus Whole Brain Radiation in PCNSL; a Nationwide Analysis. Clin Lymphoma Myeloma Leuk. 2022 May 23:S2152-2650(22)00167-7. doi: 10.1016/j.clml.2022.05.007. Epub ahead of print. PMID: 35705438.
23. Corley EM, Mustafa Ali MK*, Alharthy H, Kline KAF, Sewell D, Law JY, Lee ST, Niyongere S, Duong VH, Baer MR, Emadi A. Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study. Biology (Basel). 2022 Jun 15;11(6):916. doi: 10.3390/biology11060916. PMID: 35741439; PMCID: PMC9219926.
24. Naser AY, Alwafi H, Hemmo SI, Alrawashdeh HM, Alqahtani JS, Alghamdi SM, Mustafa Ali MK. Trends in Hospital Admissions Due to Neoplasms in England and Wales between 1999 and 2019: An Ecological Study. Int J Environ Res Public Health. 2022 Jun 30;19(13):8054. doi: 10.3390/ijerph19138054. PMID: 35805710; PMCID: PMC9265694.
25. Mustafa Ali MK, Samhouri Y, Law JY, Khan C, Wegner R, Lee ST, Lister J. Patterns of treatment and their outcomes in primary breast lymphoma; a comprehensive population-based analysis. Breast Cancer. 2022 Jul 5. doi: 10.1007/s12282-022-01382-w. Epub ahead of print. PMID: 35788963.
26. Alnimer Y, Mustafa Ali MK. Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis. Clin Lung Cancer. 2022 Aug 7:S1525-7304(22)00174-7. doi: 10.1016/j.cllc.2022.08.003. Epub ahead of print. PMID: 36008241.
27. Naser AY, Alwafi H, Hemmo SI, Alrawashdeh HM, Alqahtani JS, Alghamdi SM, Mustafa Ali MK. Trends in Hospital Admissions Due to Neoplasms in England and Wales between 1999 and 2019: An Ecological Study. Int J Environ Res Public Health. 2022 Jun 30;19(13):8054. doi: 10.3390/ijerph19138054. PMID: 35805710; PMCID: PMC9265694.
28. Awada H, Mustafa Ali MK*, Thapa B, Awada H, Seymour L, Liu L, Gurnari C, Kishtagari A, Wang E, Baer MR. A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. Cancers (Basel). 2022 Aug 28;14(17):4166. doi: 10.3390/cancers14174166. PMID: 36077703; PMCID: PMC9454629.
29. Mustafa Ali MK, Naser AY, AbuAlhommos A, Al-Daghastani T, Alrawashdeh H, Mustafa Ali S, Alwafi H, Alqurashi MM, Basha Ahmed AH, Albarqi H. Hospital Admissions Secondary to Diseases of the Blood, Blood-Forming Organs, and Immune System in England and Wales. Cureus. 2022 Oct 11;14(10):e30179. doi: 10.7759/cureus.30179. PMID: 36397897; PMCID: PMC9648385.
30. Alkhaldi H, Goloubeva O, Rapoport AP, Dahiya S, Pang Y, Mustafa Ali M, Hardy NM, Mohindra P, Bukhari A, Lutfi F, Sanchez-Petitto G, Molitoris J, Samanta S, Li X, Toth T, Landau M, Hodges S, Nishioka J, Ruehle K, Ridge L, Gahres N, Kocoglu MH, Atanackovic D, Malinou JN, Yared JA. Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience. Transplant Proc. 2023 Jan 11:S0041-1345(22)00773-4. doi: 10.1016/j.transproceed.2022.10.061. Epub ahead of print. PMID: 36635141.
31. Mustafa Ali S, Naser AY, Alghanemi AG, AbuAlhommos AK, Sabha M, Mustafa Ali MK, Hemmo SI, Alrajeh AM, Alqahtani JS, Aldhahir AM, Abu Rokbah H. Musculoskeletal System and Connective Tissue Related Hospital Admission in England and Wales Between 1999 and 2019: An Ecologic Study. Cureus. 2022 Dec 12;14(12):e32453. doi: 10.7759/cureus.32453. PMID: 36644035; PMCID: PMC9834604.
32. Al Hadidi S, Abu Zaid MI, Mustafa Ali M. Institutional disparities in the distribution of the American Society of Clinical Oncology grants. J Cancer Policy. 2023 Jan 14;35:100404. doi: 10.1016/j.jcpo.2023.100404. Epub ahead of print. PMID: 36649905.
33. Mustafa Ali MK, Williams MT, Corley EM, AlKaabba F, Niyongere S. Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2023 Apr 12:1-10. doi: 10.1080/10428194.2023.2190432. Epub ahead of print. PMID: 37042657.
34. Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 May;21(5):503-513. doi: 10.6004/jnccn.2023.0025. PMID: 37156478.
35. Lee JK, Chatterjee A, Scarpa M, Bailey CM, Niyongere S, Singh P, Mustafa Ali MK, Kapoor S, Wang Y, Silvestri G, Baer MR. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation. Cancer Res Commun. 2024 Feb 16;4(2):431-445. doi: 10.1158/2767-9764.CRC-23-0379. PMID: 38284896; PMCID: PMC10870818.
36. Ullah F, Markouli M, Orland M, Ogbue O, Dima D, Omar N, Mustafa Ali MK. Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment. Cancers (Basel). 2024 Mar 27;16(7):1307. doi: 10.3390/cancers16071307. PMID: 38610985; PMCID: PMC11011145.
37. Zureigat H, Adcock B, Nurse DP, Rauf A, Batah H, Ondeck M, Honnekeri B, Mercer M, Jia X, Rump M, Mirza KM, Al Hadidi S, Mustafa Ali MK. Navigating The 2022 International Consensus and World Health Organization Classifications of Hematopathology: A Call for Unified Diagnostic Language. Arch Pathol Lab Med. 2024 Jul 2. doi: 10.5858/arpa.2024-0031-OA. Epub ahead of print. PMID: 38952288.
38. Patel M, Zabor EC, Mohamed A, Zureigat H, Chen MJ, Nakitandwe J, Tu ZJ, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Carraway HE, Advani AS, Mustafa Ali MK. Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary center. Leuk Lymphoma. 2025 Apr 9:1-6. doi: 10.1080/10428194.2025.2482131. Epub ahead of print. PMID: 40202018.
39. Mohamed A, Zabor EC, Patel M, Zureigat H, Albliwi M, Chen MJ, Nakitandwe J, Bosler DS, Kurish H, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Carraway HE, Advani AS, Mustafa Ali MK. Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center. Clin Lymphoma Myeloma Leuk. 2025 May 19:S2152-2650(25)00173-9. doi: 10.1016/j.clml.2025.05.012. Epub ahead of print. PMID: 40500615.
40. Hanna J, Zabor EC, Albliwi M, El-Asmar J, Nurse DP, Bawwab A, Abuamsha H, Abu-Farsakh Y, Batah H, Rauf A, Nakitandwe J, Bosler DS, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Sobecks RM, Advani AS, Carraway HE, Astbury C . Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia. Am J Hematol. 2025 Jul 11. doi: 10.1002/ajh.70000. Epub ahead of print. PMID: 40642970.

Submitted Peer-Reviewed Articles

Media Appearances & Coverage / Podcasts
1. I was interviewed by CureToday to discuss the “Effects of Smoking for Breast Cancer Survivors” in 6/2016. The interview is available at: https://www.curetoday.com/view/moaath-k-mustafa-ali-on-the-effects-of-smoking-for-breast-cancer-survivors
2. I was interviewed by VuMedi to discuss the “Understanding the AML Disease State: Key Challenges and Advances” in 2/2025. The interview is available at: https://www.vumedi.com/video/understanding-the-aml-disease-state-key-challenges-and-advances/

Abstracts
1. Mustafa Ali M, Chatterjee A, Lee J, Scarpa M, Baer M; Abstract 5013: Effects of PP2A-activating drugs on FLT3 inhibitor resistance mediated by diverse mechanisms in acute myeloid leukemia with FLT3-ITD. Cancer Res 1 April 2023; 83 (7_Supplement): 5013. https://doi.org/10.1158/1538-7445.AM2023-5013
2. Adcock B, Batah H, Lee M, Patel P, Patel M, Zureigat H, Mustafa Ali MK; Can immune therapy prevent pre-clinical cancer from progression? The impact of immune therapy on secondary cancer incidence. Journal of Clinical Oncology. 2024;42(16_suppl):2651-. doi: 10.1200/JCO.2024.42.16_suppl.2651.
3. Batah H, Adcock B, Lee M, Patel P, Patel M, Zureigat H, Mustafa Ali MK; Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study. Journal of Clinical Oncology. 2024;42(16_suppl):8096-. doi: 10.1200/JCO.2024.42.16_suppl.8096.

CLINICAL ACCOMPLISHMENTS & OBLIGATIONS

1. Internal Medicine Residency
I devoted approximately 80% of my time to patient care and 20% to research. Due to the intensity of clinical responsibilities, most of my research activities were conducted outside of regular working hours. Despite that, I was able to publish 7 manuscripts, 6 of which I was the first author of.

2. Academic Hospitalist – ProMedica Toledo Hospital
Clinical Assistant Professor
As an academic hospitalist at ProMedica Toledo Hospital, I led multidisciplinary rounds involving medical students, internal medicine residents, and pharmacists. I worked across both teaching and non-teaching services, including the Internal Medicine consult service. Clinical responsibilities accounted for 100% of my time.
Despite a demanding clinical schedule, I independently designed and conducted a prospective cohort study, which culminated in a publication. I also mentored 15 internal medicine residents involved in the project. All research activities were conducted during personal time.

3. Hematology and Medical Oncology Fellowship
During my fellowship, 70% of my time was dedicated to patient care and 30% to research. Given the clinical demands, I completed all clinical research projects during my own time.
I established the AML Clinical Database at the University of Maryland, a comprehensive registry of AML patients treated since 2013.
In my allocated research time, I trained in Dr. Maria Baer’s lab, acquiring a range of laboratory techniques including:

Cell culturing and enumeration
Immunoblotting
PCR-based mRNA quantification
Cytotoxicity and combination index assays
Flow cytometry

4. Master of Public Health – Johns Hopkins University
My focus was on strengthening my biostatistical and epidemiological skills. I independently designed and analyzed over ten published clinical studies. Throughout this process, I collaborated with and mentored numerous trainees, providing guidance in study design, statistical analysis, and interpretation of results.

5. Cleveland Clinic Myeloid Neoplasm Database Registry (09/2022–present)
I collaborated with the IT department to design a high-standard registry for myeloid neoplasms at the Cleveland Clinic. I trained research coordinators on database usage and data collection protocols. Our team holds biweekly meetings, and the registry is currently active and supporting ongoing research.
The database contains data of 1000 patients with AML and 400 patients with CML, which I have collected with my team members.

6. Cleveland Clinic Solid Tumor Database Registry (09/2022–present)
I led the development of a registry for solid tumors, again in collaboration with IT, ensuring adherence to the highest data quality standards. I trained research coordinators and continue to oversee regular meetings. This registry is operational and includes data from approximately 6,300 patients.
It is the largest database for immune therapy in the world.

7. Master of Biotechnology – Johns Hopkins University
Currently enrolled, with a focus on drug development and targeted therapies in Acute Myeloid Leukemia (AML).

8. Mentorship and Teaching – International Medical Graduates
Since joining the Cleveland Clinic Foundation as a hematologist/oncologist, I have mentored approximately 60 international medical graduates. Among them, 21 pursued internal medicine residency programs, and 20 successfully matched—many at prestigious institutions, including the Cleveland Clinic’s own Internal Medicine Residency Program.

9. Mentorship and Teaching – Internal Medicine Residents
I have mentored 15 internal medicine residents during my time at the Cleveland Clinic Foundation. Of these, six applied to hematology/oncology fellowship programs, and all six successfully matched at top-tier programs, including the Mayo Clinic Hematology/Oncology Fellowship.
Several of my mentees have presented research at international medical conferences and have been interviewed by prominent medical news outlets.

10. Clinical Trials – Investigator
I have served as a co-investigator in multiple national and international clinical trials focused on leukemia and other myeloid neoplasms. My responsibilities have included patient enrollment, protocol adherence, and contributing to key clinical decisions, including dose escalation strategies in phase I trials.

COMMUNITY SERVICE / VOLUNTEER CONTRIBUTIONS
1. Humanitarian Volunteering – International Federation of Medical Students’ Associations (IFMSA) (2007–2012)
I volunteered with the International Federation of Medical Students’ Associations, an independent, non-political, non-governmental organization recognized by the World Health Organization. My work included participation in public health and medical awareness campaigns, as well as community outreach efforts serving orphans, the elderly, and environmental initiatives.

2. Humanitarian Volunteering – Operation Smile, Jordan (2010–2013)
As a volunteer with Operation Smile–Jordan, part of the global Operation Smile alliance, I helped organize and participate in medical missions aimed at providing free treatment for children and adults with facial deformities, such as cleft lips, cleft palates, and burns. These missions brought together both Jordanian and international healthcare professionals dedicated to delivering surgical care to underserved populations in Jordan and neighboring countries.

3. Public Health Research – King Hussein Cancer Center (07/2010–10/2010)
I participated in the implementation of a field survey assessing young Jordanian adults’ perceptions of proposed anti-tobacco pictorial warning labels. The results of this study informed the national policy in Jordan, with the proposed labels still in use today on tobacco products.

4. Mentorship – Jordanian Medical Students (06/2013–present)
I have mentored five Jordanian medical students, and continue to support new mentees in applying for residency programs in the United States. My mentorship includes resume and personal statement reviews, mock interviews, specialty guidance, and visa application assistance. I also offer personalized strategies to increase success in the U.S. residency match process.

5. Clinical Teaching – International Medical Students
Each month, I host 2–3 medical students from Jordan and other developing countries for clinical rotations. These rotations span both inpatient and outpatient settings and are designed to expose students to U.S. healthcare systems and best practices while fostering academic and professional development.